Navigation Links
table in Medical Technology

Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)

...s were observed in the three higher dose cohorts (50, 75 and 100 mg/day). Post-treatment viral load data suggest no evidence of drug accumulation. The table below summarizes mean HCV RNA reductions observed in this study per cohort: End of Treatment Mean Patients w...

Spherix Announces Positive Phase 2 Study Results

...naturally in small amounts in dairy products. It is a highly soluble white crystal or powder, can be produced with a physical bulk similar to ordinary table sugar, and is 92% as sweet. In the U.S., based on over 10 years of animal, human, and other relevant use and safety data, Naturlose was determined to ...

Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily

.... Registration Trial Number: NCT00125918. Page 31, table 2. (6)Galie, N., et al. "Tadalafil therapy for p.... Registration Trial Number: NCT00125918. Page 31, table 2. (9)Galie, N., et al. "Tadalafil therapy for p.... Registration Trial Number: NCT00125918. Page 32, table 2. (10)Galie, N., et al. "Tadalafil therapy for ...

Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment

...rt failure (CHF). The total cumulative doxorubicin equivalent exposure per treatment cycle for all 68 patients treated with pixantrone is noted in the table below: Treatment Cycle No. of Patients Pixantrone Lifetime Treatment...

Horizon Therapeutics' HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain

...-week treatment period. The results for each study were analyzed using both life-table and crude-rate statistical methods. Results are listed in the table below: REDUCE 1 (n=812) REDUCE 2 (n=570) HZT-501 Ibuprofen P-value HZT-501 Ibuprofen P-...

Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997

... trial report, including a complete list of adverse events and the recommended dose for Phase II studies, within three months. The following table provides a summary of the key aspects of this trial. ------------------------------------------------------------------------- Name of Trial ...

Observational Study Finds Changes in Medicare Reimbursement for Erythropoiesis-Stimulating Agents Associated With Increased Need for Blood Transfusion

...sion or recurrence in some clinical studies in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers (see WARNINGS: table 1). To decrease these risks, as well as the risk of serious cardio- and thrombovascular events, use the lowest dose needed to avoid red bloo...

42 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases

...oonotic diseases, the FAZD Center announced today. Among those innovations: A "Doc in a Box" on every American kitchen table that detects highly contagious and dangerous zoonotic diseases in people before symptoms appear. Computer-generated "lab animals" that increas...

Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting

...currence in some clinical studies in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers (see WARNINGS: table 1). -- To decrease these risks, as well as the risk of serious cardio- and thrombovascular events, use the lowest dose needed to avoid red bl...

Grapes May Aid a Bunch of Heart Risk Factors, U-M Animal Study Finds

... research needs to be done. The researchers studied the effect of regular table grapes (a blend of green, red, and black grapes) that were mixed into the r...en to reduce mild high blood pressure without medication. The dose of whole table grape powder that was consumed in the study was roughly equivalent to a per...

Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years

...ary health statistics for U.S. adults: National Health Interview Survey, 2003. National Center for Health Statistics. Vital Health Stat 10(225). 2005. table 3. ...

Clinical Trial Shows Cardiovascular Benefits of Rooibos, Popular Antioxidant Herbal Tea from South Africa

...qual to about 7 ounces, slightly less than 1 cup), brewing for 5 minutes before consumption. Subjects consumed the rooibos with or without milk and/or table sugar, as previous research on green and black teas (from the tea plant, Camellia sinensis) have demonstrated that milk does not eliminate the increas...

Cytopia Commences Second Phase II Study in Brain Cancer

...wn abnormal blood supply for growth, rendering them potentially susceptible to destruction by an anti-vascular agent such as CYT997. The following table provides a summary of the key aspects of the Phase II GBM trial. Name of trial A Phase Ib/II Study of CYT997 in Combination with ...

Amicus Therapeutics Announces Second Quarter 2008 Financial Results

... (617) 897-8294 Source: FOLD -G table 1 Amicus Therapeutics, Inc....7,083,748 22,467,198 4,051,709 22,439,893 table 2 Amicus Therapeutics, Inc....467,198 22,467,198 table 3 Amicus Therapeutics, Inc....

CellCept(R) and a Reduced Level of CNI Shows Trend Towards Preservation of Kidney Function Versus a Standard-Dose CNI

... equal to 20% of patients in CellCept group in controlled studies in prevention of renal, cardiac or hepatic allograft rejection are listed in table 8 of the ADVERSE REACTIONS section of the complete Prescribing Information. About Roche Hoffmann-La Roche Inc. (Roche), based in Nutley, N....

Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function

...led events that were reported in greater than or equal to studies in prevention of renal, cardiac or hepatic allograft rejection are listed in table 8 of the ADVERSE REACTIONS section of the complete Prescribing Information. About Roche Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J.,...

AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication

...of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000. American Journal of Gastroenterology 2003;98(7):1494-1499. table 5. (9) Mose et al. Thirty-day mortality after peptic ulcer bleeding in hospitalized patients receiving low-dose aspirin at time of admis...

New Pharma Business Model Increases Pressure on Staff Communicating Trial Data

...uster: Best Practices in Communicating Clinical Trial Results." Download the complimentary research summary of this benchmarking study including the table of contents, sample best practices and data charts at http://www3.best-in-class.com/rr948.htm . The report presents the lessons learned and best pr...

TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis

...he results for each study were analyzed using life table and crude rate methods. Results from these trial...rates for patients with EE. In one study, the life table analysis showed that 93 percent and 95 percent of ...zole 30 mg patients. In a second study, the life table analysis demonstrated that 92 percent of both 60 m...

Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine

...r topical application of TPM/Lidocaine, compared to Xylocaine(R) alone (see table 1). In addition, TPM/Lidocaine was able to increase the depth of lidocain...2.23 0.59 +/- 0.10 77.46 +/- 38.38 table 1 Dr. Esra Ogru, Executive Vice President of Research and Development at ...

InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results

...ished data describing other HCV protease inhibitors. The additional information pertains to the Day 14 median reductions in HCV RNA in this study (see table below). Mean Maximum Reduction Day 14 Median ...

InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update

...titis C virus (HCV) genotype 1 infection. InterMune reported that treatment with ITMN-191 resulted in rapid and significant reductions in HCV RNA (see table below). Total Daily Mean Maximum Reduction Cohort Dose Dose (mg) HCV RNA Log10 IU/mL (range) ...

Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache

...rug-related side effects (incidence . 5% in at least one drug dose group) reported across the three drug dose groups and placebo are listed in the table below. Placebo 1.25 mg 2.5 mg 5 mg Side Effects (%) (%) (%) ...

ORTHO EVRA(R) Prescribing Information Updated

...relative risk for VTE of 0.9 (indicating no increase in risk) and 2.4 (indicating an approximate doubling of risk). This information is presented in a table in the WARNINGS section and is available at http://www.fda.gov and http://www.orthoevra.com . The results from all of these epidemiologic studies c...

US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium

...indicated that 185 patients with a median age of 50 years (range, 24-84) were treated; 179 underwent definitive surgery. Results are summarized in the table below: Subset Number of Patients Percentage pCR Breast/A...

Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study

...of 21) who had their dose reduced, successfully completed the clinical trial with minimal safety issues. The key safety results are shown in the table below: Placebo 50mg 100mg 150mg po BID N=47 po BID N=46 po BID N=49 po BID...

Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete Remission

...a show that this superior survival benefit for Genasense-treated patients extends to all patients who achieved CR/nPR. These data are presented in the table below. Survival Genasense/Flu/Cy Flu/Cy p-value 1 year 20 8 ...

Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout

...ghest plasma drug levels (400 mg modified-release capsule twice daily), there was a 50.9% placebo-adjusted reduction in SUA (p < 0.001). The following table summarizes the results by dose group. Effect of RDEA806 on Serum Uric Acid (SUA) Levels in Phase 1 MAD Study ...

Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary

...afety and efficacy profile," concluded Dr. Jonas. table 1: Mipomersen in Routine High Cholesterol Patients...ersus a pooled placebo from all cohorts (n=14) table 2: Mipomersen Phase 1 and Phase 2 Summary of On-Tr... ALT reading *** ULN is defined to be 50 IU/L table 3: Mipomersen Phase 1 and Phase 2 Summary of Entir...

Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients

... beyond the levels they had already achieved on stable lipid-lowering therapies. ISIS 301012 treatment did not affect HDL-cholesterol (HDL-C) levels. table 1: ISIS 301012 in HeFH Patients on Maximally Tolerated Lipid-Lowering Therapies, Summary of Results. Median % changes from baseline at primary endpoi...

Beaumont Patients 1st to get Next Generation of Radiation Treatment

...to moment. Omnibeam(R) also uses robotic technology to adjust the treatment table on which a patient lies to provide pinpoint accuracy of treatment. Adjusting the radiation field and treatment table means the radiation treatment is precisely targeted to kill cancer cells, d...

Syndicom SpineConnect Web Platform Chosen for Applied Spine's Leg and Back Pain Clinical Trial of Its Stabilimax NZ(R) Dynamic Spine Stabilization System

...d learn from each others' experiences in a secure online environment. "I love the technology, because it brings people from all over the world to the table to solve real-world problems in real time," said Richard Guyer, M.D., co-founder and fellowship director of the Texas Back Institute and a principal i...

Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology

... the upper limit of normal. Efficacy results in this group of 274 patients, which are the focus of the confirmatory AGENDA trial, are displayed in the table below. (The hazard ratios indicate that the addition of Genasense to DTIC was associated with a 42% reduction in the risk of disease progression and a...

Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma

... that patients in this group achieved a significantly superior outcome (see table below). "Genasense plus dacarbazine yielded superior results in a large ra...4 patients (who are the focus of the new AGENDA trial) are displayed in the table below. The hazard ratios indicate that the addition of Genasense to DTIC wa...

MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus

...the use of teplizumab as an induction therapy in pancreatic islet cell transplantation. Additional information regarding the studies is listed in the table below. Teplizumab Clinical Trials Study Brief Description Additional Information Protege trial Global...

Amicus Therapeutics Announces Second Quarter 2007 Financial Results

...rences between U.S. GAAP EPS, net loss, research and development and general and administrative and the corresponding non-GAAP amounts are itemized in table 2, and are due to: -- Pre-tax share-based compensation expense under SFAS 123R of $1.0 million (or $0.14 per share), primarily related to employe...

Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients Presented at ACC

...results from the study will be presented in the future, as will data from the ongoing double-blind, placebo-controlled heterozygous FH study. table 1: ISIS 301012 in HoFH, Summary of Results Lipid values are presented in mg/dL and % change from baseline. Patient 1 ...

Study Presented at ACC Shows Treatment With ISIS 301012 Added to Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C Levels of Less Than 70 mg/dL

... 300 mg/week) than the 300 mg/week cohort. table 1: ISIS 301012 Coadministered with Statins, Summa...nalysis was 30 days post last dose, Day 59 table 2: ISIS 301012 Coadministered with Statins, Absol...nalysis was 30 days post last dose, Day 59 table 3: ISIS 301012 Coadministered with Statins, Patie...

Intarcia Therapeutics Announces Final Results From a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1

...r 12 weeks of treatment, and SVR, defined as undetectable HCV RNA 24 weeks after the end of 48 weeks of treatment. Response rates are presented in the table below: HCV RNA Results Omega IFN + RBV Omega IFN Alone (LOQ= 50 IU/ml) N=67 N...

Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than Vaccines Used in Previous Years

...8% and 21%). table 1 THOSE WHO HAD FLU SHOTS AND THOSE WHO G... 15 table 2 HOW MANY OF THOSE WHO GOT OR DID NOT HAV... 24 table 3 THE EXPERIENCES OF THOSE WHO BELIEV...
Other Tags
(Date:7/10/2014)... Amyloid diseases, such as Alzheimer,s disease, type ... share the common trait that proteins aggregate into ... vitro studies have found that neither the amylin ... toxic. New evidence using two-dimensional infrared (2D IR) ... amylin aggregation pathway that may explain toxicity, opening ...
(Date:7/10/2014)... Geostationary Operational Environmental Satellite or GOES-West satellite spotted ... fires raging in Canada,s Northwestern Territories. , At ... 2014, GOES-West captured this image of the brownish-colored ... Territories that drifted all the way into South ... GOES Project at NASA Goddard Space Flight Center, ...
(Date:7/10/2014)... MDBrightFocus Foundation, a nonprofit organization funding cutting-edge, innovative ... of glaucoma and macular degeneration, today announced the ... 55 scientists in 19 U.S. states, the District ... http://www.brightfocus.org/Grants2014 . , With these latest grants, ... in research funding in 2014. , The research ...
Breaking Biology News(10 mins):New technology reveals insights into mechanisms underlying amyloid diseases 2BrightFocus Foundation announces 55 new grantees in Alzheimer's and vision research 2BrightFocus Foundation announces 55 new grantees in Alzheimer's and vision research 3
(Date:7/10/2014)... Thousands of researchers from more than ... 13-17 to reveal the latest study results, theories ... in dementia science. The Alzheimer’s Association International Conference ... kind. , As part of the Alzheimer’s Association’s ... generating new knowledge about dementia and fostering a ...
(Date:7/10/2014)... his latest blog post at http://www.perwickstrom.com , entrepreneur, ... has listed 5 ways to follow-up without being annoying. ... information or sometimes even just return an inquiry, the ... skill that most people don’t have,” commented Per Wickstrom. ... moving without coming across as annoying – let alone ...
(Date:7/10/2014)... A new study from Colorado School of Public Health ... remains a major problem in the Navajo Nation and ... Native Americans is abysmal with more than three times ... Terrence Batliner, DDS, MBA, associate director of the Center ... Public Health. "The number one problem is access to ...
(Date:7/10/2014)... Teens who are sensitive to light or noise after ... such as anxiety and depression, a new study says. ... issues teens experience after concussion may help in planning ... when to return to play and what accommodations are ... Koehl and Dong Han, of the University of Kentucky ...
(Date:7/10/2014)... today,s announcement that the "Mississippi Baby," believed to have ... to have detectable levels of the virus, the Elizabeth ... setback but remains hopeful that the scientific breakthrough that ... more than two years will continue to help researchers ... cure. , "Although we had high hopes that ...
Breaking Medicine News(10 mins):Health News:Per Wickstrom’s Latest Blog Post Lists 5 Ways to Follow-up Without Being Annoying 2Health News:Study finds widespread oral health problems among Navajo 2Health News:Some Teens May Face Emotional Problems After Concussion 2Health News:Despite setback, 'Mississippi Baby' represents significant breakthrough in effort to end AIDS 2
Other Contents